Novel functions of platelets in the liver

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 4, 2016, Pages 745-751

  Kurokawa, Tomohiro ^a   Zheng, Yun Wen ^a   Ohkohchi, Nobuhiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Adenosine tri phosphate (ATP); Blood transfusion; Chronic liver disease; Cirrhosis; Eltrombopag; Hepatocyte growth factor (HGF); Kupffer cell; Liver; Liver regeneration; Liver sinusoidal endothelial cell (LSEC); Platelet; Thrombocytopenia; Thrombopoietin

Indexed keywords

ADENINE; ADENOSINE; ADENOSINE RECEPTOR; COLLAGEN; CYCLIC AMP; THROMBOPOIETIN; ADENINE NUCLEOTIDE;

CHRONIC LIVER DISEASE; COLLAGEN SYNTHESIS; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; HYPERSPLENISM; KUPFFER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER REGENERATION; LIVER SINUSOID; NONHUMAN; PRIORITY JOURNAL; REVIEW; STELLATE CELL; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; CHRONIC DISEASE; HEPATIC STELLATE CELL; LIVER DISEASES; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE;

ADENINE NUCLEOTIDES; BLOOD PLATELETS; CHRONIC DISEASE; COLLAGEN; CYCLIC AMP; HEPATIC STELLATE CELLS; HUMANS; LIVER DISEASES; LIVER REGENERATION; PLATELET TRANSFUSION; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 84963864034     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13244     Document Type: Review

References (79)

1. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin. Liver Dis. 2001; 21 (3): 397-16.
2. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LAM. Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma. Ann. N. Y. Acad. Sci. 2006; 963 (1): 13-20.
3. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. American Society for Clinical Investigation; 2005; 115 (2): 209-18.
4. Iwamoto T, Terai S, Hisanaga T et al. Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice. Cell Tissue Res. 2013; 351 (3): 487-95.
5. Kajihara M, Okazaki Y, Kato S et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J. Gastroenterol. Hepatol. 2007; 22 (1): 112-8.
6. Murata S, Ohkohchi N, Matsuo R, Ikeda O, Myronovych A, Hoshi R. Platelets Promote Liver Regeneration in Early Period after Hepatectomy in Mice. World J. Surg. 2007; 31 (4): 808-16.
7. Murata S, Matsuo R, Ikeda O et al. Platelets promote liver regeneration under conditions of Kupffer cell depletion after hepatectomy in mice. World J. Surg. 2008; 32 (6): 1088-96.
8. Matsuo R, Nakano Y, Ohkohchi N. Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. Ann. Surg. 2011; 253 (4): 759-63.
9. Kawasaki T, Murata S, Takahashi K et al. Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation. J. Hepatol. 2010; 53 (4): 648-54.
10. Matsuo R, Ohkohchi N, Murata S et al. Platelets Strongly Induce Hepatocyte Proliferation with IGF-1 and HGF In Vitro. J. Surg. Res. 2008; 145 (2): 279-86.
11. Murata S, Hashimoto I, Nakano Y, Myronovych A, Watanabe M, Ohkohchi N. Single administration of thrombopoietin prevents progression of liver fibrosis and promotes liver regeneration after partial hepatectomy in cirrhotic rats. Ann. Surg. 2008; 248 (5): 821-8.
12. Ikeda N, Murata S, Maruyama T et al. Platelet-derived adenosine 5'-triphosphate suppresses activation of human hepatic stellate cell: In vitro study. Hepatol Res. 2012; 42 (1): 91-102.
13. Watanabe M, Murata S, Hashimoto I et al. Platelets contribute to the reduction of liver fibrosis in mice. J. Gastroenterol. Hepatol. 2009; 24 (1): 78-89.
14. Maruyama T, Murata S, Takahashi K et al. Platelet transfusion improves liver function in patients with chronic liver disease and cirrhosis. Tohoku J. Exp. Med. 2013; 229 (3): 213-20.
15. Murata K, Ito K, Yoneda K, Shiraki K, Sakurai H, Ito M. Splenectomy improves liver function in patients with liver cirrhosis. Hepatogastroenterology 2008; 55 (85): 1407-11.
16. Zaldivar MM, Pauels K, von Hundelshausen P et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51 (4): 1345-53.
17. Lisman T. Platelets and fibrin in progression of liver disease: friends orfoes? J. Thromb. Haemost. 2015; 13 (1): 54-6.
18. Chang Y, Bluteau D, Debili N, Vainchenker W. From hematopoietic stem cells to platelets. J. Thromb. Haemost. 2007; 5 (s1): 318-27.
19. Nishimura S, Nagasaki M, Kunishima S et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J. Cell Biol. 2015; 209 (3): 453-66.
20. Suzuki H, Yamazaki H, Tanoue K. Immunocytochemical aspects of platelet membrane glycoproteins and adhesive proteins during activation. Prog. Histochem. Cytochem. 1996; 30 (1): 1-106.
21. Murata S, Maruyama T, Nowatari T, Takahashi K, Ohkohchi N. Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis. Int. J. Mol. Sci. 2014; 15 (4): 5412-25.
22. Holmsen H. Physiological functions of platelets. Ann. Med. 1989; 21 (1): 23-30.
23. Yamaguchi R, Terashima H, Yoneyama S, Tadano S, Ohkohchi N. Effects of platelet-rich plasma on intestinal anastomotic healing in rats: PRP concentration is a key factor. J. Surg. Res. 2012; 173 (2): 258-66.
24. Radice F, Yánez R, Gutiérrez V, Rosales J, Pinedo M, Coda S. Comparison of magnetic resonance imaging findings in anterior cruciate ligament grafts with and without autologous platelet-derived growth factors. Arthroscopy 2010; 26 (1): 50-7.
25. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc. Hematol. Disord. Drug Targets 2008; 8 (2): 99-117.
26. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002; 3 (7): 425-30.
27. Sowa JM, Crist SA, Ratliff TL, Elzey BD. Platelet influence on T- and B-cell responses. Arch. Immunol. Ther. Exp. (Warsz.) 2009; 57 (4): 235-41.
28. Pak S, Kondo T, Nakano Y et al. Platelet adhesion in the sinusoid caused hepatic injury by neutrophils after hepatic ischemia reperfusion. Platelets 2010; 21 (4): 282-8.
29. Nakano Y, Kondo T, Matsuo R et al. Platelet dynamics in the early phase of postischemic liver in vivo. J. Surg. Res. 2008; 149 (2): 192-8.
30. Lang PA, Contaldo C, Georgiev P et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat. Med. 2008; 14 (7): 756-61.
31. Flier JS, Underhill LH, Friedman SL. The Cellular Basis of Hepatic Fibrosis--Mechanisms and Treatment Strategies. N. Engl. J. Med. 1993; 328 (25): 1828-35.
32. Friedman SL. Mechanisms of Hepatic Fibrogenesis. Gastroenterology 2008; 134 (6): 1655-69.
33. Ikeda N, Murata S, Maruyama T et al. Platelet-derived adenosine 5′-triphosphate suppresses activation of human hepatic stellate cell: In vitro study. Hepatol Res 2011; 42 (1): 91-102.
34. Kodama T, Takehara T, Hikita H et al. Thrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice. Gastroenterology 2010; 138 (7): 2487-7.
35. Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte Growth Factor Attenuates Liver Fibrosis Induced by Bile Duct Ligation. Am. J. Pathol. 2006; 168 (5): 1500-12.
36. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342 (6248): 440-3.
37. Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol. Sci. 2002; 17: 6-10.
38. McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. N. Engl. J. Med. 2007; 357 (22): 2227-36.
39. Afdhal NH, Giannini EG, Tayyab G et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N. Engl. J. Med. 2012; 367 (8): 716-24.
40. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 2001; 21 (3): 373-84.
41. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J. Hepatol. 2007; 46 (5): 955-75.
42. Takahashi K, Murata S, Fukunaga K, Ohkohchi N. Human platelets inhibit liver fibrosis in severe combined immunodeficiency mice. World J. Gastroenterol. 2013; 19 (32): 5250-60.
43. Malik R, Selden C, Hodgson H. The role of non-parenchymal cells in liver growth. Semin. Cell Dev. Biol. 2002; 13 (6): 425-31.
44. Factor VM, Seo D, Ishikawa T et al. Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. Ng IOL, editor. PLoS One. 2010; 5 (9): e12739.
45. Jackson LN, Larson SD, Silva SR et al. PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294 (6): G1401-10.
46. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol. Res. 2008; 42 (1-3): 3-18.
47. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell Biol. 1999; 19 (4): 2690-8.
48. Terui K, Ozaki M. The role of STAT3 in liver regeneration. Drugs Today 2005; 41 (7): 461-9.
49. Haga S, Ozaki M, Inoue H et al. The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. Hepatology. 2009; 49 (1): 204-14.
50. Tulasne D, Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ. 2008; 15 (3): 427-34.
51. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004; 30 (2): 193-204.
52. Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K. Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis. 2003; 24 (3): 435-42.
53. Meyer J, Lejmi E, Fontana P, Morel P, Gonelle-Gispert C, Bühler L. A focus on the role of platelets in liver regeneration: Do platelet-endothelial cell interactions initiate the regenerative process? J. Hepatol. 2015; 63 (5): 1263-71.
54. Lisman T, Kirschbaum M, Porte RJ. The role of platelets in liver regeneration - What don't we know? J. Hepatol. 2015; 63 (6): 1537-8.
55. Myronovych A, Murata S, Chiba M et al. Role of platelets on liver regeneration after 90% hepatectomy in mice. J. Hepatol. 2008; 49 (3): 363-72.
56. Endo Y, Nakamura M. The effect of lipopolysaccharide, interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse. Br. J. Pharmacol. 1992; 105 (3): 613-9.
57. Kirschbaum M, Karimian G, Adelmeijer J, Giepmans BN, Porte RJ, Lisman T. Blood. 2015; 126 (6): 798-806.
58. Meijer C, Wiezer MJ, Diehl AM et al. Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy. Liver. 2000; 20 (1): 66-77.
59. Akerman P, Cote P, Yang SQ et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am. J. Physiol. 1992; 263 (4 Pt 1): G579-85.
60. Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology. 1998; 28 (4): 959-70.
61. Abshagen K, Eipel C, Kalff JC, Menger MD, Vollmar B. Loss of NF-kappaB activation in Kupffer cell-depleted mice impairs liver regeneration after partial hepatectomy. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292 (6): G1570-7.
62. Sindram D, Porte RJ, Hoffman MR, Bentley RC, Clavien PA. Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: a Kupffer cell-mediated injury. FASEB J. 2001; 15 (7): 1230-2.
63. Tamura T, Kondo T, Pak S et al. Interaction between Kupffer cells and platelets in the early period of hepatic ischemia-reperfusion injury--an in vivo study. J. Surg. Res. 2012; 178 (1): 443-51.
64. Nakamura M, Shibazaki M, Nitta Y, Endo Y. Translocation of platelets into Disse spaces and their entry into hepatocytes in response to lipopolysaccharides, interleukin-1 and tumour necrosis factor: the role of Kupffer cells. J. Hepatol. 1998; 28 (6): 991-9.
65. Hisakura K, Murata S, Takahashi K et al. Platelets prevent acute hepatitis induced by anti-fas antibody. J. Gastroenterol. Hepatol. 2011; 26 (2): 348-55.
66. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. BioMed Central 2002; 1 (1): 1.
67. Gauldie J, Richards C, Baumann H. IL6 and the acute phase reaction. Res. Immunol. 1992; 143 (7): 755-9.
68. Badia JM, Ayton LC, Evans TJ et al. Systemic cytokine response to hepatic resections under total vascular exclusion. Eur. J. Surg. 1998; 164 (3): 185-90.
69. Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, Piña E, Geller DA. Factors in the pathophysiology of the liver ischemia-reperfusion injury. J. Surg. Res. 2008; 147 (1): 153-9.
70. Yatomi Y, Ohmori T, Rile G et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood. 2000; 96 (10): 3431-8.
71. Afdhal N, McHutchison J, Brown R et al. Thrombocytopenia associated with chronic liver disease. J. Hepatol. 2008; 48 (6): 1000-7.
72. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004; 104 (9): 2623-34.
73. Khan SY, Kelher MR, Heal JM et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006; 108 (7): 2455-62.
74. Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig. Dis. Sci. 2013; 58 (6): 1790-6.
75. Sitia G, Aiolfi R, Di Lucia P et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl. Acad. Sci. U. S. A. 2012; 109 (32): E2165-72.
76. Nozaki R, Murata S, Nowatari T et al. Effects of thrombopoietin on growth of hepatocellular carcinoma: Is thrombopoietin therapy for liver disease safe or not? Hepatol Res. 2012; 43 (6): 610-20.
77. Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109 (11): 4607-16.
78. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp. Hematol. 2009; 37 (9): 1030-7.
79. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk. Res. 2010; 34 (9): 1224-31.